Darren Pan

Asst Prof @UCSFCancer
Focused on improving outcomes for multiple myeloma patients

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Link to article in @AjHematology, also adding other co-authors including @bhemato @DarrenPanMD and more.

Lots of nuances in text around recommendations above, e.g. post-ASCT maintenance and what we'd actually recommend for our own patients (and why).

https://t.co/0kQYmMWtz3

[Ajai Chari @AjaiChari]

Outstanding presentation by @AlfredChung11 on MRD dynamics in Auriga study showing benefit of daratumumab in deepening and sustained responses.

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma [DEMM] - an international myeloma working group [IMWG] immunotherapy database analysis [Nov 3, 2025] @JanakiramMurali et al. #ASH25 abs25-14454 PID 4598 https://t.co/iLZPqH9mOI #mmsm #ImmunoOnc

[Arvind Suresh @ArvindSuresh1]

How should we choose optimal salvage treatments following BCMA-directed CAR-T therapy in multiple myeloma? Check out our review article out today summarizing recent studies and our approach to therapy sequencing from our team @UCSFCancer 👇 #MMsm #myeloma

https://t.co/ab69zXWzTb

[Murali Janakiram @JanakiramMurali]

We want to share this important toxicity profile of GPRC5D BisAb- Talquetamab.
GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
https://t.co/Y4f4krHEJQ
Full link- https://t.co/CDKAxwD5J3

[Darren Pan @DarrenPanMD]

We covered the many exciting GPRC5D-based treatments on the horizon, likely to reshape how we treat myeloma - Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review

@AjaiChari @UCSFCancer

https://t.co/eAWr8E8RmN

[OncoDaily @oncodaily]

Myeloma Paper of the Day, May 6th, suggested by Robert Orlowski (@Myeloma_Doc)

@MDAndersonNews @DarrenPanMD @tarekmd91 @HJChoMDPhD1

https://t.co/dL2NCsmiHU

#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma #CART @CancerWorldmag

[Ajai Chari @AjaiChari]

Delayed cart neurotox -likely 4 risk factors demographics, disease burden, high grade crs/icans, peak CAR expansion. However rare so requires continued international collaborations- outstanding work by Dr Kumar and global contributors!

[Anupama Kumar @anupamakumar05]

Delayed neurotoxicity poster with my mentor @AjaiChari

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Why? Excellent #IMS24 plenary by Machlachlan @MSKCancerCenter 👇

PMD and EMD look very different at a genomic level, and we should stop conflating them.

Kudos to many junior faculty @ZanwarSaurabh @DimaDanai @AimazAfrough @DarrenPanMD et al who’ve helped show this clinically!

[Joshua Richter, MD, FACP @JoshuaRichterMD]

Management strategies for bispecific antibodies in myeloma. Strong work by ⁦@DarrenPanMD⁩. Ending the decades old east coast / west coast rivalry. ⁦@UCSFCancer⁩ ⁦@TischCancer⁩ #mmsm https://t.co/AmtyHOHoRb

[Mount Sinai Tisch Cancer Center @TischCancer]

Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma https://t.co/ApMCehPTOu
@DarrenPanMD @JoshuaRichterMD @IcahnMountSinai #MultipleMyeloma

[Darren Pan @DarrenPanMD]

@sridevirajeeve @JoshuaRichterMD @UCSFCancer @TischCancer That’d be me 😅

[Joshua Richter, MD, FACP @JoshuaRichterMD]

I’m beyond touched to receive this from ⁦@DarrenPanMD⁩ He says that I always have myeloma on my mind. 😀. Looking forward to years of collaboration between ⁦@UCSFCancer⁩ and ⁦@TischCancer⁩ #mmsm

[Pamela Basto, MD, PhD @PamelaBasto]

4 years later, after dark nights on the front lines of the Covid alpha wave @DOMSinaiNYC together, we're now fighting cancer in our own way. Thank you patients, donors, @ConquerCancerFd for your support in us. Barbara Murphy this one's for you! #ASCO24

[Krishna Komanduri, MD, FASTCT @drkomanduri]

And additional congrats to incoming @UCSFHospitals myeloma faculty member @DarrenPanMD and former @univmiami mentee (and @ASTCT CRTC recipient) @NikeshanJ who also received @ConquerCancerFd YIAs this past year!

[VJHemOnc @VJHemOnc]

🎥 @DarrenPanMD (@IcahnMountSinai) discusses inflammatory biomarkers that predict CAR-T efficacy in patients with #MultipleMyeloma.

Check out the interview here:

👉https://t.co/nD487dJTbH

#Myeloma #MMSM #ImmunoOnc #HemOnc #ASH23 @ASH_Hematology

[Multiple Myeloma Hub @MM_Hub]

#ASH23 | 🎥 The Multiple Myeloma Hub spoke to @DarrenPanMD, @IcahnMountSinai, US. We asked, Are chimeric antigen receptor T-cell therapies effective in the treatment of extramedullary multiple myeloma?

Watch the video here: https://t.co/CxOPczzQpW
#mmsm #myeloma #MultipleMyeloma

[The ASCO Post @ASCOPost]

Darren Denjay Pan, MD, on Multiple Myeloma: Inflammatory Biomarkers and Outcomes After CAR T-Cell Therapy https://t.co/2VwcBkh500 #ASH23 #mmsm #multiplemyeloma #hematology #biomarkers @IcahnMountSinai @TischCancer

[Joshua Richter, MD, FACP @JoshuaRichterMD]

Darren Denjay Pan on Multiple Myeloma Inflammatory Biomarkers and Outcomes After CAR T-Cell Therapy - The ASCO Post. Amazing work ⁦@DarrenPanMD⁩ #mmsm ⁦@TischCancer⁩ ⁦@MountSinaiNYC⁩ https://t.co/KYac8CXwQx